Skip to content

A clinical study comparing two unani medicines for treating dandruff (Seborrheic Dermatitis).

A Single Blind Randomised Comparative Study on the Efficacy of Unani Formulations in the Management of Iltehab Jild Huzazi (Seborrheic Dermatitis). - No

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109030
Enrollment
40
Registered
2026-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L219- Seborrheic dermatitis, unspecified

Interventions

Intervention1: Test Drugs -Arad Nakood ( Cicer arietinum), Arad Hulba ( Trigonella feonum gratum), Khatme (Althea officinalis), Khardal (Brassica nigra), Zaj e Abyaz (Alum), Sirka (Vinegar).: Topical

Sponsors

Department of Amraz e Jild wa Zohrawiya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex. Patients between age group of 14 to 60 years. Clinical diagnosed case of seborrheic dermatitis.Fine scaly lesion on scalp, face, retro auricular region, shoulder, upper chest and back, With or without itching or erythema. Patients who agreed to sign the consent form and willing to follow up.

Exclusion criteria

Exclusion criteria: Patient below 14 years of age. Patients above 60 years of age. Patients who underwent local procedures within the past 2 weeks or during the study. Patients with other concomitant skin diseases like Tinea capitis and atopic dermatitis as per history and clinical examination. Patients using other topical medications including medicated shampoos or oils or oral antifungal drugs within past 2 weeks or during course of trial. Patient with history of immunocompromised diseases such as HIV,AIDS, CKD, Diabetes. Patients who do not follow the prescribed schedule. Patients who do not want to fill consent form.

Design outcomes

Primary

MeasureTime frame
Improvement Criteria For Seborrheic Dermatitis Area Severity Index SDASI more than equal to 40 percentage reduction from baseline total SDASI score Visual confirmation of lesion reduction in extent and severity by photographic evaluation Assessment of safety by clinical examination and investigations. Timepoint: 7 th,14 th ,21 th,28 th day

Secondary

MeasureTime frame
Change in Numeric Rating Scale NRS 0 to 10 score for itching. Change in clinician-assessed erythema score 4 point scale where 0 is none to 4 is severe. Change in clinician-assessed scaling score 4 point scale where 0 is none to 4 is severe. Timepoint: 7 th,14 th ,21 th,28 th day.

Countries

India

Contacts

Public ContactShaista Parveen

Ajmal Khan Tibbiya College, Faculty of Unani Medicine, Aligarh Muslim University Aligarh

drzamiramrohi@gmail.com8475007594

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026